JB & JS open access · 2026
Proximal Femoral Varus Osteotomy Performed in the Early Stage of Legg-Calvé-Perthes Disease Increases Femoral Head Revascularization: A Serial Perfusion MRI Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Joonoh, Mistry Ahan, Kim Harry K W
Аннотация
BACKGROUND: Legg-Calvé-Perthes disease (LCPD) is idiopathic osteonecrosis of the femoral head. The effects of proximal femoral varus osteotomy (PFVO) on femoral head revascularization are unknown. We evaluated whether patients with early-stage LCPD treated with PFVO had a higher revascularization rate than those receiving nonoperative treatment with serial perfusion magnetic resonance imaging (pMRI).
METHODS: Forty-nine patients (49 hips) in early-stage LCPD with ≥2 pMRIs treated nonoperatively (n = 22) or with PFVO (n = 27) were retrospectively analyzed. The mean age of diagnosis was 8.2 ± 1.7 years (range: 5.3-12.2), median pMRI of 3 (IQR:2-4; range: 2-6), and Waldenström stage I (n = 37) or IIa (n = 12). The revascularization rate (%/month) was assessed in 4-month intervals. Time to Waldenström stage IIIb and full weight-bearing status (FWB) were compared.
RESULTS: Baseline characteristics (age, initial perfusion, Waldenström stage) were similar between groups. Perfusion was higher in the PFVO group at 4 to 8 (56 ± 20 vs. 80 ± 12%, p = 0.001) and 12 to 16 months (68 ± 25 vs. 91 ± 7%, p = 0.02) follow-ups. The PFVO group had significantly higher revascularization rates at 3 intervals: 4 to 8 (4.2 ± 2.7 vs. 7.0 ± 2.1%/month, p = 0.006), 8 to 12 (3.4 ± 1.7 vs. 6.1 ± 1.5%/month, p = 0.004), and 12 to 16 months (2.5 ± 1.3 vs. 4.9 ± 1.1%/month, p = 0.002). The PFVO group had a shorter time to Waldenström stage IIIb (22.7 ± 8.7 vs. 17.1 ± 6.9 months, p = 0.02) and was associated with earlier FWB (18.8 ± 6.5 vs. 13.1 ± 4.7 months, p = 0.008).
CONCLUSIONS: The PFVO group had faster revascularization and a shorter time to the late-reossification stage.
SIGNIFICANCE: This study is the first to investigate the effects of PFVO on revascularization rate using serial pMRI. These findings provide novel insight into the biologic effect of PFVO on femoral head revascularization.
LEVEL OF EVIDENCE: Level IV, therapeutic. See Instructions for Authors for a complete description of levels of evidence.
METHODS: Forty-nine patients (49 hips) in early-stage LCPD with ≥2 pMRIs treated nonoperatively (n = 22) or with PFVO (n = 27) were retrospectively analyzed. The mean age of diagnosis was 8.2 ± 1.7 years (range: 5.3-12.2), median pMRI of 3 (IQR:2-4; range: 2-6), and Waldenström stage I (n = 37) or IIa (n = 12). The revascularization rate (%/month) was assessed in 4-month intervals. Time to Waldenström stage IIIb and full weight-bearing status (FWB) were compared.
RESULTS: Baseline characteristics (age, initial perfusion, Waldenström stage) were similar between groups. Perfusion was higher in the PFVO group at 4 to 8 (56 ± 20 vs. 80 ± 12%, p = 0.001) and 12 to 16 months (68 ± 25 vs. 91 ± 7%, p = 0.02) follow-ups. The PFVO group had significantly higher revascularization rates at 3 intervals: 4 to 8 (4.2 ± 2.7 vs. 7.0 ± 2.1%/month, p = 0.006), 8 to 12 (3.4 ± 1.7 vs. 6.1 ± 1.5%/month, p = 0.004), and 12 to 16 months (2.5 ± 1.3 vs. 4.9 ± 1.1%/month, p = 0.002). The PFVO group had a shorter time to Waldenström stage IIIb (22.7 ± 8.7 vs. 17.1 ± 6.9 months, p = 0.02) and was associated with earlier FWB (18.8 ± 6.5 vs. 13.1 ± 4.7 months, p = 0.008).
CONCLUSIONS: The PFVO group had faster revascularization and a shorter time to the late-reossification stage.
SIGNIFICANCE: This study is the first to investigate the effects of PFVO on revascularization rate using serial pMRI. These findings provide novel insight into the biologic effect of PFVO on femoral head revascularization.
LEVEL OF EVIDENCE: Level IV, therapeutic. See Instructions for Authors for a complete description of levels of evidence.